Acute megakaryocytic leukemia: the Eastern Cooperative Oncology Group experience - PubMed (original) (raw)
. 2000 Oct 1;96(7):2405-11.
Affiliations
- PMID: 11001891
Free article
Acute megakaryocytic leukemia: the Eastern Cooperative Oncology Group experience
M S Tallman et al. Blood. 2000.
Free article
Abstract
Acute megakaryocytic leukemia (AMegL) is a rare subtype of acute myeloid leukemia (AML) evolving from primitive megakaryoblasts. Because of its rarity and the lack of precise diagnostic criteria in the past, few series of adults treated with contemporary therapy have been reported. Twenty among 1649 (1.2%) patients with newly diagnosed AML entered on Eastern Cooperative Oncology Group (ECOG) trials between 1984 and 1997 were found to have AMegL. The median age was 42.5 years (range 18-70). Marrow fibrosis, usually extensive, was present in the bone marrow. Of the 8 patients who had cytogenetic studies performed, abnormalities of chromosome 3 were the most frequent. The most consistent immunophenotypic finding was absence of myeloperoxidase in blast cells from 5 patients. In the most typical 3 cases, the leukemic cells were positive for one to 2 platelet-specific antigens in addition to lacking myeloperoxidase or an antigen consistent with a lymphoid leukemia. Myeloid antigens other than myeloperoxidase and selected T-cell antigens (CD7 and/or CD2) were frequently expressed. Induction therapy included an anthracycline and cytarabine in all cases. Complete remission (CR) was achieved in 10 of 20 patients (50%). Two patients remain alive, one in CR at 160+ months. Resistant disease was the cause of induction failure in all but 3 patients. The median CR duration was 10.6 months (range 1-160+ months). The median survival for all patients was 10.4 months (range 1-160+ months). Although half of the patients achieved CR, the long-term outcome is extremely poor, primarily attributable to resistant disease. New therapeutic strategies are needed.
Comment in
- Criteria for diagnosis of acute megakaryocytic leukemia.
Strauchen JA. Strauchen JA. Blood. 2001 Mar 15;97(6):1898. doi: 10.1182/blood.v97.6.1898. Blood. 2001. PMID: 11263442 No abstract available.
Similar articles
- The translocation t(1;22)(p13;q13) is a nonrandom marker specifically associated with acute megakaryocytic leukemia in young children.
Lion T, Haas OA, Harbott J, Bannier E, Ritterbach J, Jankovic M, Fink FM, Stojimirovic A, Herrmann J, Riehm HJ, et al. Lion T, et al. Blood. 1992 Jun 15;79(12):3325-30. Blood. 1992. PMID: 1596573 - Acute megakaryoblastic leukemia: experience of GIMEMA trials.
Pagano L, Pulsoni A, Vignetti M, Mele L, Fianchi L, Petti MC, Mirto S, Falcucci P, Fazi P, Broccia G, Specchia G, Di Raimondo F, Pacilli L, Leoni P, Ladogana S, Gallo E, Venditti A, Avanzi G, Camera A, Liso V, Leone G, Mandelli F; GIMEMA. Pagano L, et al. Leukemia. 2002 Sep;16(9):1622-6. doi: 10.1038/sj.leu.2402618. Leukemia. 2002. PMID: 12200673 Clinical Trial. - Acute myeloblastic leukemia with minimal myeloid differentiation (FAB AML-M0): a study of eleven cases.
Sempere A, Jarque I, Guinot M, Palau J, García R, Sanz GF, Gomis F, Pérez-Sirvent ML, Senent L, Sanz MA. Sempere A, et al. Leuk Lymphoma. 1993 Dec;12(1-2):103-8. doi: 10.3109/10428199309059577. Leuk Lymphoma. 1993. PMID: 8161925 - Acute megakaryoblastic leukemia in children and adolescents: a retrospective analysis of 24 cases.
Ribeiro RC, Oliveira MS, Fairclough D, Hurwitz C, Mirro J, Behm FG, Head D, Silva ML, Raimondi SC, Crist WM, et al. Ribeiro RC, et al. Leuk Lymphoma. 1993 Jul;10(4-5):299-306. doi: 10.3109/10428199309148552. Leuk Lymphoma. 1993. PMID: 8220128 Review. - Adult acute leukemia.
Cripe LD. Cripe LD. Curr Probl Cancer. 1997 Jan-Feb;21(1):1-64. doi: 10.1016/s0147-0272(97)80006-2. Curr Probl Cancer. 1997. PMID: 9058027 Review.
Cited by
- Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia.
Kuusanmäki H, Dufva O, Vähä-Koskela M, Leppä AM, Huuhtanen J, Vänttinen I, Nygren P, Klievink J, Bouhlal J, Pölönen P, Zhang Q, Adnan-Awad S, Mancebo-Pérez C, Saad J, Miettinen J, Javarappa KK, Aakko S, Ruokoranta T, Eldfors S, Heinäniemi M, Theilgaard-Mönch K, Wartiovaara-Kautto U, Keränen M, Porkka K, Konopleva M, Wennerberg K, Kontro M, Heckman CA, Mustjoki S. Kuusanmäki H, et al. Blood. 2023 Mar 30;141(13):1610-1625. doi: 10.1182/blood.2021011094. Blood. 2023. PMID: 36508699 Free PMC article. - Significance of bone marrow fibrosis in acute myeloid leukemia for survival in the real-world.
Zhang X, Wang F, Yu J, Jiang Z. Zhang X, et al. Front Oncol. 2022 Oct 7;12:971082. doi: 10.3389/fonc.2022.971082. eCollection 2022. Front Oncol. 2022. PMID: 36276150 Free PMC article. - Pediatric non-Down's syndrome acute megakaryoblastic leukemia patients in China: A single center's real-world analysis.
Zhang A, Liu L, Zong S, Chen X, Liu C, Chang L, Chen X, Yang W, Guo Y, Zhang L, Zou Y, Chen Y, Zhang Y, Ruan M, Zhu X. Zhang A, et al. Front Oncol. 2022 Oct 4;12:940725. doi: 10.3389/fonc.2022.940725. eCollection 2022. Front Oncol. 2022. PMID: 36267971 Free PMC article. - Salvage Cord Blood Transplantation for Sustained Remission of Acute Megakaryoblastic Leukemia That Relapsed Early after Myeloablative Transplantation.
Ichikawa S, Fujiwara T, Saito K, Sakurai K, Inokura K, Fukuhara N, Yokoyama H, Onodera K, Onishi Y, Kameoka J, Harigae H. Ichikawa S, et al. Intern Med. 2021 Sep 15;60(18):3015-3019. doi: 10.2169/internalmedicine.6796-20. Epub 2021 Apr 5. Intern Med. 2021. PMID: 33814495 Free PMC article. - Acute Coronary Syndrome in Acute Myeloid Leukemia with Maturation Accompanying Megakaryocytic Differentiation.
Odani K, Abe J, Tsuyuki Y, Yanagita S, Shiogama K, Tachibana M, Tsutsumi Y. Odani K, et al. Case Rep Pathol. 2020 Sep 18;2020:8886298. doi: 10.1155/2020/8886298. eCollection 2020. Case Rep Pathol. 2020. PMID: 33014496 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous